Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
Dostarlimab Gets Positive EU Opinion in Recurrent or Advanced MSI-H Endometrial Cancer
February 26th 2021February 26, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion to dostarlimab as a treatment for patients with recurrent or advanced microsatellite instability–high/mismatch repair deficient endometrial cancer who have progressed on or following platinum-based chemotherapy.
Read More
Combos Lead Excitement in BRAF+ Melanoma, But More Pain Points Are Ready to Be Tackled
February 18th 2021Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.
Read More
VHL Disease: Monitoring Is Imperative, But Research Efforts Are Gaining Ground
February 16th 2021VHL disease is defined as a rare, inherited disorder that causes tumors and cysts to grow in specific areas of the body, including the brain, spinal cord, eyes, inner ear, adrenal glands, pancreas, kidney, and reproductive tract.
Read More
NBTXR3 Activity in Soft Tissue Sarcoma Could Be Replicated in Other Cancers
February 15th 2021NBTXR3, a novel radioenhancer, is showing intriguing response rates in adult patient with soft tissue sarcoma, paving a path for the innovative therapy not just in sarcomas, but other tumor types, as well.
Read More
Off Our Chests: John Marshall, MD, and Liza Marshall Recount Her TNBC Journey
February 15th 2021John Marshall, MD, and his wife, Liza, recount the challenging journey of Liza's triple-negative breast cancer (TNBC) diagnosis and how John's career as a gastrointestinal oncologist played into the caregiving process. The interview comes ahead of the release of their book, Off Our Chests, which goes further in depth with their experience.
Read More
Orca-T Displays GVHD Prevention, Scalability Potential, and Tolerability in Hematologic Cancers
February 11th 2021February 11, 2021 - Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.
Read More
Narsoplimab Shows Impressive Responses, Survival Benefit in High-Risk HSCT-TMA
February 9th 2021February 8, 2021 — Narsoplimab demonstrated clinical activity and a favorable survival benefit in patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, according to updated results of a pivotal phase 2 trial.
Read More
Future of Frontline EGFR+ NSCLC Features TKI, Chemo Combos and Improved Molecular Profiling
February 7th 2021Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant non–small cell lung cancer to the next level.
Read More
Schilsky Says Farewell as Retirement From ASCO Approaches
February 1st 2021Richard L. Schilsky, MD, FACP, FSCT, FASCO, sat down to share his proudest moments and obstacles throughout his career with ASCO, as well as advice for his successor, Julie Gralow, MD, who will step into the position on February 15, 2021.
Read More
Pembrolizumab/Ipilimumab Combo Does Not Improve Survival, Shows Higher Toxicity in PD-L1+ NSCLC
January 30th 2021January 29, 2021 - Pembrolizumab plus ipilimumab did not improve survival and had higher rates of toxicity versus pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer who had a PD-L1 tumor proportion score of 50% or greater, and did not harbor EGFR or ALK aberrations.
Read More
Sotorasib Elicits Rapid Responses, Encouraging PFS in Advanced KRAS G12C+ NSCLC
January 29th 2021January 28, 2021 - Treatment with the KRAS G12C inhibitor sotorasib (formerly AMG 510) elicited a 6.8-month median progression-free survival in patients with KRAS G12C–mutated advanced non–small cell lung cancer.
Read More
Real-World Study Confirms NRG1 Fusions in NSCLC, Supports Afatinib Studies
January 28th 2021January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.
Read More
Bioengineered Models Could Improve Understanding of Bone Cancer, Metastases
January 26th 2021R. Lor Randall, MD, FACS, discusses the rationale and motivation behind tissue-engineered platforms and how they could significantly impact the understanding of how cancer arises in or metastasizes to bone.
Read More
Could Orca-T Unlock New Path of Reduced Mortality, Prevent GVHD Posttransplant?
January 18th 2021Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.
Read More
Ivosidenib Induces OS Benefit in Advanced IDH1+ Cholangiocarcinoma
January 17th 2021January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the final overall survival analysis of the phase 3 ClarIDHy trial.
Read More
Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer
January 16th 2021Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
Adjuvant S-1/Docetaxel Combo Shows Survival Improvement in Stage III Gastric Cancer
January 15th 2021January 15, 2021 - Combination treatment with adjuvant S-1 and docetaxel led to an estimated 29% reduction in the risk of relapse compared with S-1 alone in patients with stage III gastric cancer.
Read More